Loading
A phase 2 trial of Osimertinib, Furmonertinib, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., now recruiting.
A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC) is a phase 2 interventional study registered as NCT07622186 by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., with 150 participants planned, started 2026-07-15 and due to reach its primary completion in 2028-12-31. Interventions recorded: SKB571 for injection, Osimertinib, Furmonertinib, carboplatin, Cisplatin. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Sichuan Kelun-Biotech, Osimertinib, Carboplatin, Small-cell lung cancer.
Shares Furmonertinib, Osimertinib, Cisplatin, Carboplatin.
Shares Osimertinib, Cisplatin, Carboplatin, Small-cell lung cancer.
Shares Sichuan Kelun-Biotech, Osimertinib, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Sichuan Kelun-Biotech, Small-cell lung cancer, Pembrolizumab, Non-small-cell lung cancer.
Shares Osimertinib, Cisplatin, Carboplatin, Small-cell lung cancer.
Shares Sichuan Kelun-Biotech, Cisplatin, Carboplatin, Small-cell lung cancer.
Shares Sichuan Kelun-Biotech, Cisplatin, Carboplatin, Small-cell lung cancer.